126 related articles for article (PubMed ID: 17692217)
1. [Skin lesions in a female patient with non-Hodgkin lymphoma].
Ducasse VO; Pintado JA; Gordon MM; Oyonarte MC
Enferm Infecc Microbiol Clin; 2007; 25(7):489-90. PubMed ID: 17692217
[No Abstract] [Full Text] [Related]
2. Cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) plus rituximab is effective and well tolerated in poor performance status elderly patients with non-Hodgkin's lymphoma.
Visani G; Guiducci B; D'Adamo F; Mele A; Nicolini G; Leopardi G; Sparaventi G; Barulli S; Malerba L; Isidori A; Malagola M; Piccaluga PP
Leuk Lymphoma; 2005 Mar; 46(3):477-9. PubMed ID: 15621843
[No Abstract] [Full Text] [Related]
3. [Supportive care for patients with non-Hodgkin lymphoma receiving R-CHOP chemotherapy].
Kato H
Nihon Rinsho; 2015 Feb; 73 Suppl 2():636-41. PubMed ID: 25831838
[No Abstract] [Full Text] [Related]
4. Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab.
Lim KH; Yoon HI; Kang YA; Lee KW; Kim JH; Bang SM; Lee JH; Lee CT; Lee JS
Korean J Intern Med; 2010 Mar; 25(1):86-92. PubMed ID: 20195409
[TBL] [Abstract][Full Text] [Related]
5. Rituximab plus CHOP as an initial chemotherapy for patients with disseminated MALT lymphoma.
Ennishi D; Yokoyama M; Mishima Y; Watanabe C; Terui Y; Takahashi S; Takeuchi K; Ikeda K; Tanimoto M; Hatake K
Leuk Lymphoma; 2007 Nov; 48(11):2241-3. PubMed ID: 17990181
[No Abstract] [Full Text] [Related]
6. Phase I trial examining addition of gemcitabine to CHOP in intermediate grade NHL.
Reagan JL; Rosmarin A; Butera JN; Nadeem A; Schiffman FJ; Sikov WM; Winer E; Mega AE
Cancer Chemother Pharmacol; 2011 Oct; 68(4):1075-80. PubMed ID: 21761371
[TBL] [Abstract][Full Text] [Related]
7. Precore mutant hepatitis B reactivation after treatment with CHOP-rituximab.
Zell JA; Yoon EJ; Ignatius Ou SH; Hoefs JC; Chang JC
Anticancer Drugs; 2005 Jan; 16(1):83-5. PubMed ID: 15613909
[TBL] [Abstract][Full Text] [Related]
8. Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.
Case DC; Desch CE; Kalman LA; Vongkovit P; Mena RR; Fridman M; Allen B
Clin Lymphoma Myeloma; 2007 Mar; 7(5):354-60. PubMed ID: 17562245
[TBL] [Abstract][Full Text] [Related]
9. Rituximab-associated neutropenia.
Dunleavy K; Tay K; Wilson WH
Semin Hematol; 2010 Apr; 47(2):180-6. PubMed ID: 20350665
[TBL] [Abstract][Full Text] [Related]
10. Point prevalence of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma according to the number of cycles of R-CHOP chemotherapy.
Kim T; Choi SH; Kim SH; Jeong JY; Woo JH; Kim YS; Sung H; Kim MN; Yoon DH; Suh C; Lee SO
Ann Hematol; 2013 Jan; 92(2):231-8. PubMed ID: 23053189
[TBL] [Abstract][Full Text] [Related]
11. Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma.
Bermúdez A; Marco F; Conde E; Mazo E; Recio M; Zubizarreta A
Haematologica; 2000 Aug; 85(8):894-5. PubMed ID: 10942955
[No Abstract] [Full Text] [Related]
12. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma.
Sparano JA; Lee JY; Kaplan LD; Levine AM; Ramos JC; Ambinder RF; Wachsman W; Aboulafia D; Noy A; Henry DH; Von Roenn J; Dezube BJ; Remick SC; Shah MH; Leichman L; Ratner L; Cesarman E; Chadburn A; Mitsuyasu R;
Blood; 2010 Apr; 115(15):3008-16. PubMed ID: 20023215
[TBL] [Abstract][Full Text] [Related]
13. Sarcoid-like reaction in the spleen following chemotherapy for non-Hodgkin's lymphoma.
Reilly TB; Schuster DM; Starsiak MD; Kost CB; Halkar RK
Clin Nucl Med; 2007 Jul; 32(7):569-71. PubMed ID: 17581351
[No Abstract] [Full Text] [Related]
14. Three cases of Pneumocystis jirovecii pneumonia (PCP) during first-line treatment with rituximab in combination with CHOP-14 for aggressive B-cell non-Hodgkin's lymphoma.
Venhuizen AC; Hustinx WN; van Houte AJ; Veth G; van der Griend R
Eur J Haematol; 2008 Mar; 80(3):275-6. PubMed ID: 18005387
[No Abstract] [Full Text] [Related]
15. Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma.
Kilickap S; Yavuz B; Aksoy S; Sahiner L; Dincer M; Harputluoglu H; Erman M; Aytemir K; Tokgozoglu L; Barista I
Med Oncol; 2008; 25(4):437-42. PubMed ID: 18415035
[TBL] [Abstract][Full Text] [Related]
16. Overview of Southwest Oncology Group Clinical Trials in non-Hodgkin Lymphoma. S0016. A phase III trial of CHOP vs CHOP + rituximab vs CHOP + iodine131-labeled monoclonal anti-B1 antibody (tositumomab) for treatment of newly diagnosed follicular NHL.
Fisher RI
Clin Adv Hematol Oncol; 2005 Jul; 3(7):544-6. PubMed ID: 16167036
[No Abstract] [Full Text] [Related]
17. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911.
Press OW; Unger JM; Braziel RM; Maloney DG; Miller TP; LeBlanc M; Gaynor ER; Rivkin SE; Fisher RI
Blood; 2003 Sep; 102(5):1606-12. PubMed ID: 12738671
[TBL] [Abstract][Full Text] [Related]
18. A prospective study of left ventricle function after treatment with rapid-infusion rituximab in patients with non-Hodgkin lymphoma.
Provencio M; Sanchez A; Maximiano C; Cantos B; Méndez M; Bonilla F
Leuk Lymphoma; 2009 Oct; 50(10):1642-6. PubMed ID: 19757315
[TBL] [Abstract][Full Text] [Related]
19. Large gastrosplenic fistula after effective treatment of abdominal diffuse large-B-cell lymphoma.
Palmowski M; Zechmann C; Satzl S; Bartling S; Hallscheidt P
Ann Hematol; 2008 Apr; 87(4):337-8. PubMed ID: 17929016
[No Abstract] [Full Text] [Related]
20. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma.
Coiffier B
Tumori; 2002; 88(1 Suppl 1):S26-8. PubMed ID: 11989916
[No Abstract] [Full Text] [Related]
[Next] [New Search]
